BiotechTube
Korsana Biosciences

Korsana Biosciences

San Diego, United States· Est.
korsana.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $175M

Overview

Korsana Biosciences is a private, pre-clinical-stage biotech company targeting neurodegenerative diseases with a novel BBB-penetrant shuttle platform. The company emerged from stealth in February 2026 with $175 million in funding to advance its lead program, KRSA-028, a shuttled monoclonal antibody for Alzheimer's disease. Led by a seasoned team and backed by prominent life science investors, Korsana aims to overcome a fundamental challenge in CNS drug development by enabling effective biologic delivery to the brain.

Neurodegenerative DiseasesAlzheimer's Disease

Technology Platform

Therapeutic Targeting (THETA™), a novel blood-brain barrier (BBB)-penetrant shuttle platform designed to enhance CNS exposure of large-molecule biologics, developed in partnership with Paragon Therapeutics.

Funding History

1
Total raised:$175M
Venture$175M

Opportunities

The successful development of the THETA™ platform could unlock the vast potential of biologic therapies for neurodegenerative diseases, addressing a massive unmet need in Alzheimer's and other CNS disorders.
Validation of the lead program could lead to lucrative partnerships, pipeline expansion into other indications, or positioning the company as an acquisition target for larger pharma.

Risk Factors

The company faces high preclinical/clinical risk as its novel BBB shuttle technology is unproven in humans.
It operates in the highly competitive and scientifically challenging Alzheimer's disease space, and its value is currently concentrated in a single lead asset, creating significant binary risk.

Competitive Landscape

Korsana competes with other companies developing BBB shuttle technologies (e.g., bioconjugation, receptor-mediated transport) and directly with developers of anti-amyloid and other neurodegenerative disease biologics. It must differentiate its THETA™ platform on efficacy, safety, and manufacturability against both established and emerging modalities.

More companies in Biologics / Biosimilars →More companies in United States →